TABLE 1.
Patient characteristics
| Characteristic* | Overall, N = 41 | Yoga, N = 21 | WLC, N = 20 |
|---|---|---|---|
| Patient age | 61.7 (35.5, 79.0) | 60.0 (35.5, 77.9) | 62.3 (42.4, 79.0) |
| Body mass index | 26.6 (17.8, 35.9) | 26.6 (18.7, 35.5) | 26.5 (17.8, 35.9) |
| Race | |||
| White | 23 (56.1%) | 11 (52.4%) | 12 (60.0%) |
| Black | 8 (20.0%) | 4 (19.0%) | 4 (20.0%) |
| Asian | 5 (12.2%) | 4 (19.0%) | 1 (5.0%) |
| Unknown | 5 (12.2%) | 2 (9.5%) | 3 (15.0%) |
| Ethnicity | |||
| Hispanic | 2 (4.9%) | 1 (4.8%) | 1 (5.0%) |
| Non‐Hispanic | 39 (95.1%) | 20 (95.2%) | 19 (95.0%) |
| Cancer type | |||
| Breast | 38 (92.7%) | 18 (85.7%) | 20 (100.0%) |
| Uterine | 2 (4.9%) | 2 (9.5%) | 0 (0%) |
| Ovary | 1 (2.4%) | 1 (4.8%) | 0 (0%) |
| Cancer stage | |||
| Stage I | 11 (26.8%) | 6 (28.6%) | 5 (25.0%) |
| Stage II | 15 (36.6%) | 5 (23.8%) | 10 (50.0%) |
| Stage III | 13 (31.7%) | 9 (42.9%) | 4 (20.0%) |
| Other | 2 (4.9%) | 1 (4.8%) | 1 (5.0%) |
| Years Since Diagnosis | 3.9 (0.9, 25.8) | 3.5 (0.9, 25.8) | 4.1 (1.3, 15.8) |
| Years Since CTx End | 3.1 (0.5, 15.3) | 3.1 (0.5, 10.4) | 3.7 (0.9, 15.3) |
| Type of CTx | |||
| Carboplatin | 1 (2.4%) | 1 (4.8%) | 0 (0.0%) |
| Docetaxel | 2 (4.9%) | 2 (9.5%) | 0 (0.0%) |
| Docetaxel & Carboplatin | 3 (7.3%) | 2 (9.5%) | 1 (5.0%) |
| Paclitaxel | 33 (80.5%) | 14 (66.7%) | 19 (95.0%) |
| Paclitaxel & Carboplatin | 2 (4.9%) | 2 (9.5%) | 0 (0.0%) |
Abbreviations: CTx, Chemotherapy; WLC, Wait‐list Control.
*
Statistics presented: median (minimum, maximum); n (%).